Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Baas, Dean Anthony Fennell, Keith M. Kerr et al. · Annals of Oncology · 2015
Cited by 417 works. doi:10.1093/annonc/mdv199 Open-access PDF
Authors
References
- TNM Classification of Malignant Tumours
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
- Pathology and genetics of tumours of the lung , pleura, thymus and heart
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients
- A Proposed New International TNM Staging System for Malignant Pleural Mesothelioma
- A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma
- Germline BAP1 mutations predispose to malignant mesothelioma
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients